news
Anti-viral COVID-19 nasal spray to be commercialised
Birmingham Biotech and the University of Birmingham, UK, have signed a licensing agreement for an anti-viral nasal spray against COVID-19.
List view / Grid view
Drug Markets
article
The race to get biotech innovation to market: five steps to success
Achieving prompt and profitable market access for new pharma products has never been more challenging. Next-generation drug launches are increasing in number year on year, creating strong competition, and treatments are becoming more tightly targeted, reducing the size of available markets. In addition, biologic drugs are highly complex and expensive…
article
Towards a solution for the access challenges faced by combination treatments
In this article, Takeda UK present their Value Attribution and Voluntary Arbitration Frameworks, a potential solution for the combination treatment challenge.
news
Smart use of off-patent medicines critical for post-COVID healthcare
2021 Medicines for Europe-IGBA conference speakers assert that off-patent medicines will be crucial to rebuild healthcare post-COVID-19.
news
Indian active pharmaceutical ingredients market to grow by 12.24 percent
The Indian active pharmaceutical ingredients (APIs) market stood at $11.8 billion in 2021 and continues to grow, says market report.
news
(Bio)pharma continuous manufacturing market to reach $2.3 billion by 2027
The continuous manufacturing market for pharma/biopharma is expected to expand at a compound annual growth rate of 13.85 percent.
news
ViroCell Biologics and GOSH to address gene and cell therapy “logjam”
ViroCell Biologics and Great Ormond Street Hospital (GOSH) partner to tackle the viral vector manufacturing bottleneck for clinical trials.
news
EMA’s human medicines committee (CHMP) September meeting highlights
In its most recent meeting, the CHMP recommended nine new medicines and concluded its review of Vaxzevria’s thrombosis risk.
news
US government purchases additional 1.4 million doses of REGEN-COV™
Regeneron announced a new US government agreement to purchase additional doses of REGEN-COV (casirivimab and imdevimab) antibody cocktail.
news
Viral vector purification market expected to reach over $1 billion by 2028
New research suggests the viral vector purification market will attain a compound annual growth rate of 14.2 percent between 2021 and 2028.
article
Embedding inclusion in pharmaceutical design
In this article, Included’s Raafi-Karim Alidina explores biases in product design, outlining how they impact pharmaceuticals as well as technologies, and practical steps to enhance diversity and ensure inclusion.
news
FDA reaches over 100 Competitive Generic Therapy approvals
The FDA reached the milestone of approving more than 100 generic drug applications with a Competitive Generic Therapy designation.
article
Six major disruptors for the generics and biosimilars market
In this article, EPR's Hannah Balfour outlines six factors that could significantly challenge the generics and biosimilars market in the next decade.
article
UK life sciences sector: do you have the Vision for innovation?
Here, EPR explores some highlights of the UK’s new Life Sciences Vision for the pharma, biopharma and biotech industries, covering topics from funding to regulatory reviews and clinical trial innovation.
![Gloved hand holding a vial labelled 'COVID-19 Vaccine' with Pfizer and BioNTech logos [Credit: malazzama / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Pfizer-BioNTech-COVID-19-vaccine-300x278.jpg)
![Gloved hand holding a vial labelled 'COVID-19 Vaccine' with Pfizer and BioNTech logos [Credit: malazzama / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Pfizer-BioNTech-COVID-19-vaccine-e1629795881701.jpg)
news
Pfizer-BioNTech becomes the first FDA-approved COVID-19 vaccine
Pfizer and BioNTech's vaccine is the first to be approved by the FDA for the prevention of COVID-19 in people aged 16 years and older.
